Adherence to Antiretroviral Therapy during and after Pregnancy: Cohort Study on Women Receiving Care in Malawi's Option B+ Program

Clinical Infectious Diseases

Volumn 63, Issue 9, 2016, Pages 1227-1235

  Haas, Andreas D ^a   Msukwa, Malango T ^a,d   Egger, Matthias ^a,c   Tenthani, Lyson ^a,e   Tweya, Hannock ^a,f,j   Jahn, Andreas ^e,g   Gadabu, Oliver J ^d   Tal, Kali ^a   Salazar Vizcaya, Luisa ^a,b   Estill, Janne ^a   Spoerri, Adrian ^a   Phiri, Nozgechi ^a   Chimbwandira, Frank ^g   Van Oosterhout, Joep J ^h,i   Keiser, Olivia ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d BAOBAB HEALTH TRUST   (Malawi)

^e International Training and Education Center for Health   (United Kingdom)

^f Lighthouse Trust   (United Kingdom)

^g MINISTRY OF HEALTH   (Malawi)

^h DIGNITAS INTERNATIONAL   (Malawi)

ⁱ UNIVERSITY OF MALAWI   (Malawi)

^j INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

more..

Author keywords

adherence; antiretroviral therapy; HIV; mother to child transmission; Option B+

Indexed keywords

EFAVIRENZ PLUS LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; AGE; ANTIVIRAL THERAPY; ARTICLE; BILLING AND CLAIMS; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; FEMALE; HEALTH CENTER; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALAWI; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PHARMACY; PREGNANCY; PREGNANT WOMAN; PRENATAL CARE; PRIORITY JOURNAL; PUBLIC HOSPITAL; RISK FACTOR; WORLD HEALTH ORGANIZATION; YOUNG ADULT; COHORT ANALYSIS; COMBINATION DRUG THERAPY; MALE; PATIENT CARE; POSTNATAL CARE; PREGNANCY COMPLICATION; PUBLIC HEALTH;

ADULT; ANTI-HIV AGENTS; BREAST FEEDING; COHORT STUDIES; CONTINUITY OF PATIENT CARE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALAWI; MALE; MEDICATION ADHERENCE; NATIONAL HEALTH PROGRAMS; POSTNATAL CARE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; YOUNG ADULT;

EID: 84994496742     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw500     Document Type: Article

References (40)

1. Schouten EJ, Jahn A, Midiani D, et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet 2011; 378:282-4.
2. Ministry of Health Malawi. Clinical management of HIV in children and adults, 2014. Available at: http://cms.medcol.mw/cms-uploaded-resources/18381-16. pdf. Accessed 2 August 2016.
3. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2013. Available at: http://apps.who.int/iris/bitstream/10665/ 85321/1/9789241505727-eng.pdf. Accessed 26 June 2015.
4. Tenthani L, Haas AD, Tweya H, et al. Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women ('Option B+') in Malawi. AIDS 2014; 28:589-98.
5. Centers for Disease Control and Prevention. Impact of an innovative approach to prevent mother-to-child transmission of HIV-Malawi, July 2011-September 2012. MMWR Morb Mortal Wkly Rep 2013; 62:148-51.
6. Coutsoudis A, Goga A, Desmond C, Barron P, Black V, Coovadia H. Is Option B+ the best choice? Lancet 2013; 381:269-71.
7. Haas AD, Tenthani L, Msukwa MT, et al. Retention in care during the first 3 years of antiretroviral therapy for women in Malawi's option B+ programme: an observational cohort study. Lancet HIV 2016; 3:e175-82.
8. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and highincome countries: a systematic review and meta-analysis. AIDS 2012; 26: 2039-52.
9. Henegar CE, Westreich DJ, Maskew M, Miller WC, Brookhart MA, Van Rie A. Effect of pregnancy and the postpartum period on adherence to antiretroviral therapy among HIV-infected women established on treatment. J Acquir Immune Defic Syndr 2015; 68:477-80.
10. Koss CA, Natureeba P, Mwesigwa J, et al. Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women. AIDS 2015; 29:825-30.
11. Matthews LT, Ribaudo HB, Kaida A, et al. HIV-infected Ugandan women on antiretroviral therapy maintain HIV-1 RNA suppression across periconception, pregnancy, and postpartum periods. J Acquir Immune Defic Syndr 2016; 71:399-406.
12. Okonji JA, Zeh C,Weidle PJ, et al. CD4, viral load response, and adherence among antiretroviral-naive breast-feeding women receiving triple antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV in Kisumu, Kenya. J Acquir Immune Defic Syndr 2012; 61:249-57.
13. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007; 146:564-73.
14. Garcia PM, Kalish LA, Pitt J, et al. Women and Infants Transmission Study Group. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999; 341:394-402.
15. Chi BH, Cantrell RA, Zulu I, et al. Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. Int J Epidemiol 2009; 38:746-56.
16. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 2006; 43:78-84.
17. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003; 37:1112-8.
18. Douglas GP, Gadabu OJ, Joukes S, et al. Using touchscreen electronic medical record systems to support and monitor national scale-up of antiretroviral therapy in Malawi. PLoS Med 2010; 7:e1000319.
19. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006; 40:1280-8.
20. Ranganathan P, Pramesh C. Censoring in survival analysis: potential for bias. Perspect Clin Res 2012; 3:40.
21. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496-509.
22. McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis 2011; 52:493-506.
23. Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM. Adherence to antiretroviral therapy and virologic failure: a meta-analysis. Medicine (Baltimore) 2016; 95: e3361.
24. Tweya H, Gugsa S, Hosseinipour M, et al. Understanding factors, outcomes and reasons for loss to follow-up among women in Option B+ PMTCT programme in Lilongwe, Malawi. Trop Med Int Health 2014; 19:1360-6.
25. Robins JM, Rotnitzky A, Zhao LP. Analysis of semiparametric regression models for repeated outcomes in the presence of missing data. J Am Stat Assoc 1995; 90:106-21.
26. Rubin DB. Inference and missing data. Biometrika 1976; 63:581-92.
27. van Lettow M, Bedell R, Mayuni I, et al. Towards elimination of mother-to-child transmission of HIV: performance of different models of care for initiating lifelong antiretroviral therapy for pregnant women in Malawi (Option B+). J Int AIDS Soc 2014; 17:18994.
28. Dow A, Dube Q, Pence BW, Van Rie A. Postpartum depression and HIV infection among women in Malawi. J Acquir Immune Defic Syndr 2014; 65:359-65.
29. Conrad P. The meaning of medications: another look at compliance. Soc Sci Med 1985; 20:29-37.
30. Zhou A. The uncertainty of treatment: women's use of HIV treatment as prevention in Malawi. Soc Sci Med 2016; 158:52-60.
31. Miller CM, Ketlhapile M, Rybasack-Smith H, Rosen S. Why are antiretroviral treatment patients lost to follow-up? a qualitative study from South Africa. Trop Med Int Health 2010; 15(suppl 1):48-54.
32. Sustiva (efavirenz). Available at: http://www.pdr.net/full-prescribing-information/ Sustiva-efavirenz-116. Accessed 2 August 2016.
33. Kim MH, Zhou A, Mazenga A, et al. Why did I stop? barriers and facilitators to uptake and adherence to ART in option B+ HIV care in Lilongwe, Malawi. PLoS One 2016; 11:e0149527.
34. Adakun SA, Siedner MJ, Muzoora C, et al. Higher baseline CD4 cell count predicts treatment interruptions and persistent viremia in patients initiating ARVs in rural Uganda. J Acquir Immune Defic Syndr 2013; 62:317-21.
35. Grimsrud A, Cornell M, Schomaker M, et al. CD4 count at antiretroviral therapy initiation and the risk of loss to follow-up: results from a multicentre cohort study. J Epidemiol Community Health 2016; 70:549-55.
36. Harrigan PR, Hogg RS, Dong WWY, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191:339-47.
37. Phillips T, Brittain K, Mellins CA, et al. A self-reported adherence measure to screen for elevated HIV viral load in pregnant and postpartum women on antiretroviral therapy. AIDS Behav 2016; doi:10.1007/s10461-016-1448-0.
38. Wilkinson LS. ART adherence clubs: a long-term retention strategy for clinically stable patients receiving antiretroviral therapy. South Afr J HIV Med 2013; 14:48.
39. Mills EJ, Lester R, Thorlund K, et al. Interventions to promote adherence to antiretroviral therapy in Africa: a network meta-analysis. Lancet HIV 2014; 1: e104-11.
40. Nachega JB, Skinner D, Jennings L, et al. Acceptability and feasibility of mHealth and community-based directly observed antiretroviral therapy to prevent mother-to-child HIV transmission in South African pregnant women under Option B+: an exploratory study. Patient Prefer Adherence 2016; 10:683-90.